panitumumab

High Alert

Treatment of wild-type RAS (wild type in KRAS and NRAS) metastatic colorectal cancer that has failed fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy (to be used as monotherapy).
Treatment of wild-type RAS (wild type in KRAS and NRAS) metastatic colorectal cancer (as first-line therapy with FOLFOX).

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Concurrent use of leucovorin;
RAS: mutant metastatic colorectal cancer or unknown RAS mutation status (↑ mortality and tumor progression);
OB: Pregnancy;
Lactation: Lactation.

Use Cautiously in:

Rep: Women of reproductive potential;
Pedi: Safety and effectiveness not established in children.

Adv. Reactions/Side Effects ⬆ ⬇

CV: edema

Derm: acneiform dermatitis, dry skin, erythema, paronychia, pruritus, rash, skin exfoliation, skin fissures, abscesses, NECROTIZING FASCIITIS, photosensitivity

EENT: corneal perforation, eyelash growth, keratitis, ulcerative keratitis

F and E: hypocalcemia, hypomagnesemia

GI: abdominal pain, constipation, diarrhea, nausea, vomiting, stomatitis

GU: acute renal failure

Neuro: fatigue

Resp: cough, INTERSTITIAL LUNG DISEASE (ILD), PULMONARY FIBROSIS

Misc: INFUSION REACTIONS, SEPSIS

Interactions ⬆ ⬇

Drug-drug:

None reported.

Availability ⬆ ⬇

Solution for injection: 20 mg/mL

Route/Dosage ⬆ ⬇

IV (Adults ): 6 mg/kg every 14 days.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Binds to epidermal growth factor receptor resulting in inactivation of kinases that regulate proliferation and transformation.

Therapeutic effects:

Decreased progression of colorectal cancer.

Classifications ⬆ ⬇

Therapeutic Classification: antineoplastics

Pharmacologic Classification: kinase inhibitors

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-Life: 7.5 days.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
IV	unknown	end of infusion	unknown

Patient/Family Teaching ⬆ ⬇

Explain purpose of panitumumab to patient.
May cause photosensitivity. Caution patient to wear sunscreen and hats and to limit sun exposure.
Advise patient to notify health care professional if signs and symptoms of dermatologic toxicity, infusion reactions, pulmonary fibrosis, or ocular changes occur.
Rep: May cause fetal harm. Advise females of reproductive potential to use effective contraception and to avoid breastfeeding during and for 2 months after last dose. May impair fertility in females.
Emphasize the need for periodic blood tests to monitor electrolyte levels.

section name header

Indications ⬇